Cheplapharm Arzneimittel GmbH’s €780 Million Financing


Heuking Kühn Lüer Wojtek and White & Case advised on the transaction

Cheplapharm Arzneimittel GmbH finalized the refinancing of existing loans and promissory note loans.

The new credit facilities with a total volume of EUR 780 million were concluded with Deutsche Bank, HSBC, and Unicredit on the London capital market. Commerzbank, DZ Bank, and Santander additionally support the placement with international investors.

The new credit facilities provide the group with flexible and sustainable long-term financing. In addition to the repayment of existing loans and promissory notes, significant additional liquidity will be available to finance future product acquisitions. The new financing structure offers Cheplapharm significant increases in flexibility at attractive terms. The international market for long-term loans (TLB market) also offers the option of flexible increases to support future growth.

CHEPLAPHARM Arzneimittel GmbH is an internationally operating, family-run pharmaceutical company headquartered in the Hanseatic city of Greifswald with some 200 employees and annual sales of EUR 316 million. It has subsidiaries in Hamburg, Englewood, New Jersey, and France. Founded in 1998, the company produces and sells branded and niche pharmaceutical products worldwide, both in the prescription and OTC segments.

Heuking Kühn Lüer Wojtek advised Cheplapharm Arzneimittel GmbH with a team including Thomas K. W. Schrell, LL.M. (Lead, Picture) and Anja Harms (Banking & Finance).

White & Case advised the Bank Syndicate with a team including Vanessa Schuermann, Florian Ziegler, Sébastien Seele, Daniel Rogits and Lisa Kirchner.

Involved fees earner: Thomas Schrell – Heuking Kühn Lüer Wojtek; Anja Harms – Heuking Kühn Lüer Wojtek; Vanessa Schürmann – White & Case; Florian Ziegler – White & Case; Lisa Kirchner – White & Case;

Law Firms: Heuking Kühn Lüer Wojtek; White & Case;

Clients: Commerzbank AG; Deutsche Bank AG London Branch; UniCredit Bank AG; Hsbc Bank plc; Dz Bank; Santander Consumer Bank AG; Cheplapharm Arzneimittel GmbH;